| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9327403 | Gynecologic Oncology | 2005 | 4 Pages |
Abstract
The dose and schedule of liposomal doxorubicin employed in this trial showed no advantage over historical results with doxorubicin in the treatment of uterine leiomyosarcoma.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Gregory Sutton, John Blessing, Parviz Hanjani, Paul Kramer,